Previous 10 | Next 10 |
PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propr...
2023-11-01 04:02:35 ET Summary PDSB provided updated interim data from its Versatile-002 study of PDS0101 in early October. While the survival data are strong, there were no responses in checkpoint inhibitor-refractory patients. Versatile-003 is set to get underway in Q4'23. The t...
Combination of PDS0101 and KEYTRUDA ® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity Lowered CD8 T cells in peripheral blood after treatment align with previously reported CD8 T cell targeting and a...
2023-10-11 08:56:30 ET More on PDS Biotechnology PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study The Prognosis For PDS Biotechnology PDS Biotech updates Phase 2 data for lead asse...
First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301). Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301. The combinati...
2023-10-03 08:51:33 ET More on PDS Biotech PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study The Prognosis For PDS Biotechnology PDS Biotech gains after updates on pivotal trial for...
Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival rate of less than 30% for approved ICI 1 . Received feedback from US Food and Drug Administra...
Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) treatment Patients treated with PDS0101 had greater clearance of cfDNA as compared to those ...
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s prop...
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunoth...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NYSE Market:
PDS Biotechnology Corporation Website:
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15,...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...